Amgen says drug combo cuts death risk 58% in aggressive lung cancer

Amgen reports that its drug, combined with an AstraZeneca immunotherapy, could give patients with an aggressive lung cancer more time to live. Per the CNBC item, the company says the combo cuts the risk of death by 58%.

Timeline

1. 24 Oct, 14:30 UTCCNBC reports Amgen's 58% death-risk claim

Top sources

• Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancerCNBC